[1]曾普华.从炎性微环境探析肿瘤恶液质的“癌毒致虚”病机观[J].陕西中医,2021,(8):987-990,1137.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.001]
　ZENG Puhua.Analysis of the “cancer toxin-induced deficiency” pathogenesis of tumor cachexia from the inflammatory microenvironment[J].,2021,(8):987-990,1137.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.001]
点击复制

从炎性微环境探析肿瘤恶液质的“癌毒致虚”病机观
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年8期
页码:
987-990,1137
栏目:
述评
出版日期:
2021-08-05

文章信息/Info

Title:
Analysis of the “cancer toxin-induced deficiency” pathogenesis of tumor cachexia from the inflammatory microenvironment
作者:
曾普华
(湖南省中医药研究院附属医院,湖南 长沙 410006)
Author(s):
ZENG Puhua
(Affiliated Hospital of Hunan Academy of Chinese Medicine,Changsha 410006,China)
关键词:
肿瘤;  恶液质;  炎性微环境;  癌毒致虚;  细胞因子;  中医理论
Keywords:
Tumor;  Cachexia;  Inflammatory microenvironment;  Deficiency caused by cancer toxicity;  Cytokines;  TCM theory
分类号:
R 73
DOI:
DOI:10.3969/j.issn.1000-7369.2020.08.001
文献标志码:
A
摘要:
炎症被视为肿瘤的第七大生物学特征,而肿瘤被称作“永不愈合的伤口”。炎性微环境作为肿瘤微环境的重要组成部分,不仅诱导正常细胞向肿瘤细胞转化,导致肿瘤的发生,还通过分泌炎性细胞因子、趋化因子参与上皮-间质转化、血管新生、代谢重编程等过程,促进肿瘤侵袭、转移及恶液质的发生。中医学认为,癌毒与痰浊、瘀血、热毒相互滋助、互为因果,胶结留着于至虚之处而发为肿瘤。癌毒窃夺精血、损耗正气,使机体出现“虚劳”之候,体现了肿瘤恶液质 “癌毒致虚” 的病机特点。本文总结分析了炎性微环境在肿瘤恶液质发生发展中的关键作用,并探析其与中医学“癌毒致虚”病机理论的相关性,为“癌毒致虚”治疗肿瘤恶液质提供科学依据。
Abstract:
Inflammation is regarded as the seventh biological feature of tumors,and tumors are called “non-healing wounds”.As an important part of the tumor microenvironment,the inflammatory microenvironment not only induces the transformation of normal cells into tumor cells,leading to the occurrence of tumors,but also participates in epithelial-mesenchymal transition,angiogenesis,and metabolism by secreting inflammatory cytokines and chemokines.Programming and other processes promote tumor invasion,metastasis and the occurrence of cachexia.Traditional Chinese medicine believes that cancer toxins,phlegm,blood stasis,and heat toxin help each other and act as cause and effect.The cement remains in the most deficient place and develops into a tumor.Cancer toxin steals the essence and blood and depletes the righteous energy,causing the body to appear “deficiency”,which reflects the pathogenesis characteristics of tumor cachexia “cancer-toxin-induced deficiency”.This article summarizes and analyzes the key role of the inflammatory microenvironment in the occurrence and development of tumor cachexia,and explores its correlation with the pathogenesis theory of “cancer toxin-induced deficiency” in Chinese medicine.

参考文献/References:

[1] 樊 盼,陆建荣,姚俊涛.颗粒蛋白前体在肿瘤发生和发展中的作用研究进展[J].陕西医学杂志,2020,49(7):910-913.
[2] Anker MS,Holcomb R,Muscaritoli M,et al.Orphan disease status of cancer cachexia in the USA and in the European Union:A systematic review[J].Cachexia Sarcopenia Muscle,2019,10(1):22-34.
[3] Baracos VE,Martin L,Korc M,et al.Cancer-associated cachexia[J].Nat Rev Dis Primers,2018,18(4):171-185.
[4] Balkwill F,Mantovani A.Inflammation and cancer:Back to virchow?[J].Lancet,2001,357(9255):539-545.
[5] Singh N,Baby D,Rajguru JP,et al.Inflammation and cancer[J].Ann Afr Med,2019,18(3):121-126.
[6] Coussens LM,Werb Z.Inflammation and cancer[J].Nature,2002,420(6917):860-867.
[7] Hudson JD,Shoaibi MA,Maestro R,et al.A proinflammatory cytokine inhibits p53 tumor suppressor activity[J].Exp Med,1999,190(10):1375-1382.
[8] Kim J,Bae JS.Tumor-associated macrophages and neutrophils in tumor microenvironment[J].Mediators Inflamm,2016,3(1):605-614.
[9] Schoppmann S.Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis[J].Am J Pathol,2002(161):947-956.
[10] Mantovani A,Bottazzi B,Colotta F,et al.The origin and function of tumor-associated macrophages[J].Immunol Today,1992(13):265-270.
[11] Wang X,Lin Y.Tumor necrosis factor and cancer,buddies or foes?[J].Acta Pharmacol Sin,2008(29):1275-1288.
[12] Robinson SC,Scott KA,Balkwill FR.Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha[J].Eur J Immunol,2002,32(2):404-412.
[13] Nagarsheth N,Wicha MS,Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J].Nat Rev Immunol,2017,17(9):559-572.
[14] Fisher DT,Appenheimer MM,Evans SS.The two faces of IL-6 in the tumor microenvironment[J].Semin Immunol,2014,26(1):38-47.
[15] Vanhoutte G, Wiel M,Wouters K,et al.Cachexia in cancer:What is in the definition?[J].BMJ Open Gastroenterology,2016,3(1):92-97.
[16] Kamp CM,Langen RC,Snepvangers FJ,et al.Nuclear transcription factor κB activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia[J].Am J Clin Nutr,2020(98):738-748.
[17] 张 颖,王新颖.癌性恶液质骨骼肌蛋白降解机制[J].肿瘤代谢与营养电子杂志,2020,7(3):255-258.
[18] Webster JM,Kempen LJ,Hardy RS,et al.Inflammation and skeletal muscle wasting during cachexia front physiol[J].Frontiers in Physiology,2020,19(11):597-615.
[19] 董亚冰,王楠娅.脂肪组织与恶液质——白色棕色的敌友之争[J].肿瘤代谢与营养电子杂志,2017,4(3):267-271.
[20] Nishio M,Saeki K.The remaining mysteries about brown adipose tissues[J].Cells,2020,9(11):2449-2461.
[21] Han J,Meng Q,Shen L,et al.Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning[J].Lipids Health Dis,2018,17(1):1-14.
[22] Campos CA,Bowen AJ,Han S,et al.Cancer-induced anorexia and malaise are mediated by CGRP neurons in the parabrachial nucleus[J].Nat Neurosci,2017,20(7):934-942.
[23] Fujitsuka N,Asakawa A,Uezono Y,et al.Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival[J].Transl Psychiatry,2011,1(7):1-23.
[24] 程海波,吴勉华.周仲瑛教授“癌毒”学术思想探析[J].中华中医药杂志,2010,25(6):866-869.
[25] 沈政洁,程海波,沈卫星,等.肿瘤炎性微环境与“癌毒”病机相关性探讨[J].北京中医药大学学报,2015,38(1):14-17.
[26] 李克雄,曾普华,郜文辉,等.基于“癌毒致虚”理论探讨肿瘤恶病质的中医药治疗[J].亚太传统医药,2019,15(10):90-92.
[27] 孙海燕,华杭菊,任丽萍,等.试从肺脾肾三脏论癌性恶病质[J].光明中医,2019,34(21):3247-3249.
[28] 欧阳钦,吴春明.薯蓣丸膏方辅助治疗肝癌恶病质40例临床疗效分析[J].中国高等医学教育,2012,26(6):126-127.
[29] 胡成琳,胡陵静,叶海英,等.参苓白术散对肿瘤恶病质患者TNF-α、TWEAK、Fn14表达的影响[J].重庆医科大学学报,2019,44(7):950-953.
[30] 张蕴超,贾英杰,朱津丽,等.消岩汤联合榄香烯注射液治疗癌症恶病质41例临床观察[J].中医杂志,2016,57(7):574-578.
[31] 高 震,杨 静,贺雪黛,等.“消癌解毒方”对晚期肿瘤恶液质患者生活质量及外周血IL-6、TNF-α的影响——附30例临床资料[J].江苏中医药,2020,52(12):22-25.
[32] 徐 玲,张学进,杨国良.四君子汤对癌性恶病质小鼠血清细胞因子的影响[J].中华中医药学刊,2015,33(4):907-910.
[33] 韩正祥,谢晓东,高向阳,等.益气清热养阴中药对肺癌恶病质小鼠的免疫调节作用[J].实用医学杂志,2010,26(4):572-574.
[34] 张蕴超,贾英杰,杨佩颖,等.中药消岩汤对肺癌恶病质大鼠摄食的瘦素抵抗机制研究[J].中国中西医结合杂志,2014,34(12):1512-1516.
[35] 郭 苇,肖 敏,左 谦,等.参芪扶正注射液对结肠癌小鼠恶液质后骨骼肌线粒体功能的影响[J].中草药,2019,50(24):6059-6063.
[36] 刘 婷,丁 艳,杨婷婷,等.鲜枸杞子提取物通过p38 MAPK信号通路抑制人肝癌细胞HepG2诱导小鼠恶病质的作用及机制[J].中国实验方剂学杂志,2019,25(9):89-94.

相似文献/References:

[1]黄越秀,陈光伟,张家墉△,等.陈光伟教授治疗肿瘤根治术后肠麻痹经验[J].陕西中医,2020,(11):1654.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.036]
[2]张小力,刘 芹,刘宝瑞.重楼皂苷抗肿瘤及调节肿瘤免疫微环境研究进展[J].陕西中医,2021,(11):1640.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.033]
　ZHANG Xiaoli,LIU Qin,LIU Baorui.Advances in anti-tumor effects of paris saponins[J].,2021,(8):1640.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.033]
[3]王中会,晁 旭,吕天依,等.土贝母苷甲抗肿瘤作用机制研究进展[J].陕西中医,2021,(11):1652.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.036]
　WANG Zhonghui,CHAO Xu,LYU Tianyi,et al.Research progress on the Anti-solid tumor mechanism of TBMSⅠ[J].,2021,(8):1652.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.036]
[4]张美英,张 英,侯 炜.基于数据挖掘探讨黄芪抗肿瘤复方的临床应用[J].陕西中医,2023,(7):957.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.031]
[5]冯薪宇,罗富锟,胡利来,等.肿瘤中医病机发展与“辨病识机”指导意义[J].陕西中医,2025,46(2):237.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.019]
　FENG Xinyu,LUO Fukun,HU Lilai,et al.The innovative development of TCM tumor pathogenesis and the guiding significance of “disease identification machine”[J].,2025,46(8):237.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.019]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助面上项目(82074425); 青年岐黄学者支持项目; 湖南省121创新人才工程项目; 湖南创新型省份建设专项经费资助项目(2019SK4013)
更新日期/Last Update: 2021-08-09